CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Down 97.5% in December

CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totaling 49,357 shares, a decline of 97.5% from the December 15th total of 1,939,991 shares. Based on an average daily volume of 27,586,017 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 27,586,017 shares, the short-interest ratio is presently 0.0 days.

CNBX Pharmaceuticals Stock Down 20.0%

CNBX Pharmaceuticals stock opened at $0.00 on Tuesday. CNBX Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.02.

About CNBX Pharmaceuticals

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.